Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 7, 2026; 32(33): 117979
Published online Sep 7, 2026. doi: 10.3748/wjg.117979
Published online Sep 7, 2026. doi: 10.3748/wjg.117979
Naringenin pretreatment attenuates hepatic ischemia-reperfusion injury by activating the PI3K-Akt signaling pathway
Jian-Sen Lu, Hong-Liang Liang, First Central Hospital, Tianjin Medical University, Tianjin 300192, China
De-Cheng Chen, Beijing Anzhen Hospital, Capital Medical University, Beijing 100011, China
Hao Pan, Tian Han, School of Medicine, Nankai University, Tianjin 300071, China
Wei-Ye Zhang, Wen Hou, Zhong-Yang Shen, Tianjin Organ Transplantation Research Center, Institute of Transplantation Medicine, Tianjin First Central Hospital, Nankai University, Tianjin 300071, China
Meng Fan, Department of Orthopedics, Tianjin First Central Hospital, Nankai University, Tianjin 300071, China
Co-first authors: Jian-Sen Lu and Hong-Liang Liang.
Co-corresponding authors: Wen Hou and Zhong-Yang Shen.
Author contributions: Lu JS and Liang HL contributed equally as co-first authors; Shen ZY and Hou W designed the study and contributed equally as co-corresponding authors; Lu JS, Liang HL, Chen DC, and Pan H conducted animal and molecular experiments; Lu JS and Hou W prepared the first draft of the manuscript; Han T, Zhang WY, Fan M, Hou W, and Shen ZY modified the manuscript. All authors approved the final version of the manuscript.
Supported by Natural Science Foundation of Tianjin City, No. 23JCZDJC01070; Tianjin Key Medical Discipline Construction Project, No. TJYXZDXK-3-006A and No. TJYXZDXK-3-005A; National Natural Science Foundation of China, No. 82241219; and National Major Scientific Research Instrument Development Project of China, No. 82127808.
Institutional animal care and use committee statement: The animal study was reviewed and approved by the Animal Ethics Committee of Nankai University, No. 2024-SYDWLL-000215.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: Data will be made available on request.
Corresponding author: Zhong-Yang Shen, MD, Tianjin Organ Transplantation Research Center, Institute of Transplantation Medicine, Tianjin First Central Hospital, Nankai University, No. 94 Fukang Road, Nankai District, Tianjin 300071, China. zhongyangshen@nankai.edu.cn
Received: December 22, 2025
Revised: February 4, 2026
Accepted: April 27, 2026
Published online: September 7, 2026
Processing time: 231 Days and 18.1 Hours
Revised: February 4, 2026
Accepted: April 27, 2026
Published online: September 7, 2026
Processing time: 231 Days and 18.1 Hours
Core Tip
Core Tip: The specific protective effects and underlying molecular mechanisms in hepatic ischemia-reperfusion injury remain to be systematically elucidated. This study demonstrates that naringenin protects the liver from ischemia-reperfusion injury by inhibiting oxidative stress, inflammatory response, and hepatocyte apoptosis, with the phosphatidylinositol